EANS-Adhoc: Sartorius AG / Preliminary Figures for the First Half of 2011

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

22.07.2011

Group sales revenue rises 12.2% to EUR353.7 million | Consolidated
operating earnings soar 40.7% to EUR51.1 million; the respective
margin improves to 14.4%| Management raises full-year guidance for
sales revenue and profit

In the first half of 2011, order intake for the Sartorius Group grew
13.6%currency-adjusted: +14.6%) from EUR336.4 million to
EUR382.3 million. Sales revenue rose 12.2% (currency-adj.: +13.1%) to
EUR353.8 million from EUR315.2 million in the previous year. The
Biotechnology Division received orders valued at EUR257.2 million, up
16.2% (currency-adj.: +17.4%) from EUR221.4 million a year ago, and
increased its sales revenue year on year by 9.7% (currency-adj.:
+10.8%) to EUR229.4 million from EUR209.1 million. For the
Mechatronics Division,order intake climbed 8.7% (currency-adj.:
+9.2%) to EUR125.1 million from EUR115.1 million a year earlier; the
division´s revenue grew 17.2% (currency-adj.: +17.6%) to EUR124.3
million from EUR106.1 million a year ago.

Consolidated underlying EBITA surged from EUR36.3 million to EUR51.1
million; this reflects earnings before interest, taxes and
amortization and is adjusted for extraordinary items of -EUR6.7
million (prev. yr.: -EUR1.9 mn). The respective margin jumped from
11.5% to 14.4%. The Biotechnology Division contributed an underlying
EBITA of EUR38.6 million, up from EUR31.5 million a year ago, which
means its margin increased from 15.0% to 16.8%. The Mechatronics
Division more than doubled its contribution to earnings, from EUR4.8
million to EUR12.4 million; its earnings margin jumped from 4.5% to
10.0%.

Excluding non-cash amortization, underlying net profit after minority
interest for the first half totaled EUR24.0 million (prev. year:
EUR15.9 mn); the respective earnings per share were at EUR1.41, up
from EUR0.93 a year ago.

Based on the Group's first-half figures, management has raised its
2011 full- year guidance for sales revenue and profit, and now
projects that sales in constant currencies will grow for both
divisions and thus also for the Group between 8% and 10% (former
guidance: 6% to 8%). The underlying EBITA margin is forecasted to
increase in constant currencies to between 17% and 18% for the
Biotechnology Division (former guidance: about 17%) and to between
10% and 11% for the Mechatronics Division (former guidance: about
8%). Accordingly, the operating EBITA margin at Group level is
expected to improve to between 14.5% and 15.5% (former guidance:
about 14%). Moreover, management continues to anticipate that in 2011
operating cash flow will be significantly positive.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Monday, July
25, 2011, at 4:00 p.m. Central European Time in a webcast
teleconference. You may dial into the teleconference starting at
3:45 p.m. CET at the following numbers: Germany +49 (0)69 2222 2244;
France +33(0)1 70 99 42 73; UK +44(0)20 7136 2052; USA +1 212 444
0481. The dial-in code is as follows: 9817884

The webcast and presentation can be viewed at www.sartorius.com.

Goettingen, July 22, 2011

-----------------------
Sartorius AG
37070 Goettingen, Germany

Andreas Wiederhold

Phone +49(0)551.308.1668
Fax +49(0)551.308.3153
andreas.wiederhold@
sartorius.com
www.sartorius.com

|Ad hoc Announcement |[pic]
|

Further inquiry note:
Henriette Meyer
Treasury & Investor Relations
Tel.: +49 (0)551-308-3232
E-Mail: henriette.meyer@sartorius.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Sartorius AG
Weender Landstr. 94-108
D-37075 Göttingen
phone: +49 (0)551 308-0
FAX: +49 (0)551 308-3289
mail: info.investor@sartorius.com
WWW: http://www.sartorius.com
sector: Biotechnology
ISIN: DE0007165607, DE0007165631
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English